Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
23.8M
-
Number of holders
-
22
-
Total 13F shares, excl. options
-
2.26M
-
Shares change
-
+1.21M
-
Total reported value, excl. options
-
$4.6M
-
Value change
-
+$2.46M
-
Put/Call ratio
-
0
-
Number of buys
-
10
-
Number of sells
-
-12
-
Price
-
$2.05
Significant Holders of NRX Pharmaceuticals, Inc. - Common Stock, $0.001 par value (NRXP) as of Q1 2025
32 filings reported holding NRXP - NRX Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q1 2025.
NRX Pharmaceuticals, Inc. - Common Stock, $0.001 par value (NRXP) has 22 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.26M shares
of 23.8M outstanding shares and own 9.51% of the company stock.
Largest 10 shareholders include Anson Funds Management LP (1.18M shares), VANGUARD GROUP INC (389K shares), AdvisorShares Investments LLC (287K shares), GEODE CAPITAL MANAGEMENT, LLC (135K shares), MARSHALL WACE, LLP (89.1K shares), STATE STREET CORP (43.7K shares), TWO SIGMA INVESTMENTS, LP (30.1K shares), BlackRock, Inc. (29.1K shares), NORTHERN TRUST CORP (28.6K shares), and One Wealth Management Investment & Advisory Services, LLC (15K shares).
This table shows the top 22 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.